Summary: This roundtable discussion offers a closer look at oncology's hottest fields, including CAR-T and precision medicine, 2021's biggest research trends and the data they're most looking forward to seeing.

Summary: Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors.

Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.

Summary: Gwen Green, VP of Commercial Excellence at Catalent, and Endpoints News editors highlight the top 20 women in biopharma who have made it to the upper echelons of the drug development business in this on-demand webinar.

Summary: Karen Flynn, President of Biologics and Chief Commercial Officer, explains the challenges and opportunities changing how biomedical supply chains must plan and innovate to continue to serve patients and build resilient future options.

Summary: Download this webinar to hear various approaches to generate batch comparability results for a biosimilar glycoprotein and vaccine candidate

Catalent offers a comprehensive suite of analytical services for traditional biologics and advanced therapies such as antibody-drug conjugates (ADCs), cell and gene therapies, and mRNA vaccines, including drug substance, drug product and intermediates, at our biologics analytical sites in the United States.

Summary: The FDA requires that host cell proteins (HCPs) be reduced to low levels because they can affect the safety and efficacy of a drug. Pharmaceutical Technology recently spoke with...

Summary: Bioassays and binding assays play a critical role in ensuring product quality, safety and efficacy.

Summary: Analytical testing for biologics is evolving rapidly as new protocols become available and companies seek to expedite current methodologies.